NASDAQ:XBIT - XBiotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.55 +0.07 (+0.83 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$8.48
Today's Range$8.36 - $8.56
52-Week Range$2.13 - $10.70
Volume2,321 shs
Average Volume209,047 shs
Market Capitalization$306.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.70 per share

Profitability

Net Income$-33,150,000.00

Miscellaneous

Employees51
Market Cap$306.26 million
Next Earnings Date3/15/2019 (Estimated)
OptionableOptionable

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

When is XBiotech's next earnings date?

XBiotech is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for XBiotech.

Has XBiotech been receiving favorable news coverage?

Media headlines about XBIT stock have been trending somewhat positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. XBiotech earned a news impact score of 1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.14%) and Virtu Financial LLC (0.04%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.

Which institutional investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold XBiotech company stock in the last year include Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

Which institutional investors are buying XBiotech stock?

XBIT stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $8.55.

How big of a company is XBiotech?

XBiotech has a market capitalization of $306.26 million. XBiotech employs 51 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is http://www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 WINNEBAGO LN, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]


MarketBeat Community Rating for XBiotech (NASDAQ XBIT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel